Citadel Advisors - XERIS BIOPHARMA HOLDINGS INC ownership

XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 104 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q2 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of XERIS BIOPHARMA HOLDINGS INC
ValueSharesWeighting
Q3 2023$600,955
-38.7%
323,094
-13.6%
0.00%
Q2 2023$979,618
+251.7%
373,900
+118.8%
0.00%
Q1 2023$278,567
-24.4%
170,900
-38.3%
0.00%
Q4 2022$368,463
-7.9%
277,040
+8.3%
0.00%
Q3 2022$400,000
-28.1%
255,750
-29.1%
0.00%
Q2 2022$556,000
-45.0%
360,923
-8.5%
0.00%
Q1 2022$1,010,000
-48.4%
394,414
-40.9%
0.00%
Q4 2021$1,956,000667,5470.00%
Other shareholders
XERIS BIOPHARMA HOLDINGS INC shareholders Q2 2022
NameSharesValueWeighting ↓
CAXTON CORP 6,039,028$9,843,61624.86%
Stonepine Capital Management, LLC 8,640,205$14,083,5344.72%
Alpine Global Management, LLC 400,000$652,0000.25%
DELTEC ASSET MANAGEMENT LLC 622,072$1,013,9770.25%
XTX Topco Ltd 233,385$380,4180.08%
Redmile Group, LLC 1,046,587$1,705,9370.07%
GSA CAPITAL PARTNERS LLP 316,025$5150.05%
Yakira Capital Management, Inc. 90,076$146,8240.04%
IHT Wealth Management, LLC 281,442$458,7620.03%
TUDOR INVESTMENT CORP ET AL 960,111$1,5650.02%
View complete list of XERIS BIOPHARMA HOLDINGS INC shareholders